[vc_row full_width=“stretch_row_content_no_spaces“ el_class=“procedure-hero“][vc_column][vc_single_image image=“2840″ img_size=“full“ alignment=“center“ el_class=“no-mb infinite-image desktop-image“][vc_single_image image=“3347″ img_size=“full“ alignment=“center“ el_class=“no-mb infinite-image mobile-image“][vc_custom_heading text=“Management Team“ font_container=“tag:h1|text_align:left|color:%23ffffff|line_height:1″ use_theme_fonts=“yes“][vc_raw_html el_class=“no-mb“]JTNDaDYlMjBjbGFzcyUzRCUyMmhlYWQtYnJlYWRjcnVtYiUyMiUzRSUzQ2ElMjBocmVmJTNEJTIyJTJGZGUlMkYlMjIlM0VTdGFydHNlaXRlJTNDJTJGYSUzRSUyMCUyRiUyME1hbmFnZW1lbnR0ZWFtJTNDJTJGaDYlM0U=[\/vc_raw_html][\/vc_column][\/vc_row][vc_row full_width=“stretch_row“ css=“.vc_custom_1639056771797{padding-top: 0px !important;padding-bottom: 40px !important;background-color: #ffffff !important;}“][vc_column width=“1\/4″][vc_single_image image=“6205″ img_size=“full“ el_class=“no-mb“][\/vc_column][vc_column width=“3\/4″][vc_column_text el_class=“directors no-mb“]<\/p>\n
Jim Hollingshead verf\u00fcgt \u00fcber mehr als drei Jahrzehnte globale F\u00fchrungserfahrung in der Medizintechnik und den Life Sciences. Seine Karriere ist gepr\u00e4gt von der erfolgreichen Markteinf\u00fchrung und Skalierung kategoriepr\u00e4gender Produkte. Vor seinem Eintritt bei BVI f\u00fchrte Jim zweimal Unternehmen durch transformative Phasen und erzielte dabei f\u00fchrende Marktpositionen, nachhaltiges profitables Wachstum sowie sp\u00fcrbare Verbesserungen im Leben von Patientinnen und Patienten.<\/p>\n
Als President und CEO der Insulet Corporation von 2022 bis 2025, nachdem er zun\u00e4chst als unabh\u00e4ngiges Vorstandsmitglied t\u00e4tig war, verantwortete Jim die Einf\u00fchrung bahnbrechender Technologien, die Wettbewerber \u00fcberholten und Insulet als Nummer-eins-Anbieter in seiner Kategorie positionierten. Seine F\u00fchrung verband Produktvision mit kommerzieller Disziplin und \u00fcbersetzte Innovation in eine schnelle Marktdurchdringung.<\/p>\n
Zuvor bekleidete Jim mehrere leitende Positionen bei ResMed, darunter President des Gesch\u00e4ftsbereichs Sleep and Respiratory Care, President Americas, Chief Strategy Officer sowie President Ventures & Initiatives. Dort leitete er die Konzeption und Einf\u00fchrung cloudbasierter Angebote, die die vernetzte Versorgung neu definierten und die Wettbewerbslandschaft der Branche nachhaltig ver\u00e4nderten. Jim begann seine Karriere in der Strategieberatung, wo er globale Organisationen branchen\u00fcbergreifend beriet, und ist heute Mitglied des Verwaltungsrats von Vantive, einem f\u00fchrenden Medizintechnikunternehmen im Bereich der Nierenversorgung. Er erwarb einen BA an der Stanford University sowie einen Master- und Doktortitel an der University of California, Berkeley.[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=“stretch_row“ css=“.vc_custom_1639056771797{padding-top: 0px !important;padding-bottom: 40px !important;background-color: #ffffff !important;}“][vc_column width=“1\/4″][vc_single_image image=“6221″ img_size=“full“ el_class=“no-mb“][\/vc_column][vc_column width=“3\/4″][vc_column_text el_class=“directors no-mb“]<\/p>\n
Andrew Chang bringt \u00fcber 20 Jahre Erfahrung in der kommerziellen Leitung in den Bereichen ophthalmologische Medizintechnik und Pharmazie mit und hatte F\u00fchrungspositionen in einigen der weltweit renommiertesten Unternehmen der Branche inne.<\/p>\n
Er begann seine Karriere im Finanzwesen und in fr\u00fchen Gesch\u00e4ftsrollen, bevor er in die Ophthalmologie wechselte, wo er bei ISTA Pharmaceuticals und sp\u00e4ter bei Bausch + Lomb zunehmend leitende Positionen im kommerziellen Bereich \u00fcbernahm. Bei ISTA war er ma\u00dfgeblich an der erfolgreichen Einf\u00fchrung mehrerer ophthalmologischer Produkte beteiligt. Nach der \u00dcbernahme von ISTA durch Bausch + Lomb \u00fcbernahm er erweiterte Aufgaben bei OptiMedica, das kurz darauf an Abbott Medical Optics verkauft wurde. Schlie\u00dflich war er General Manager und Senior Vice President bei Bausch + Lomb Surgical und verantwortete Vertrieb, Marketing, Betrieb und Gesch\u00e4ftsentwicklung in den USA.<\/p>\n
Sp\u00e4ter wechselte er zu ZEISS Medical Technology, wo er als Pr\u00e4sident von Carl Zeiss Meditec USA, Inc. und Leiter des weltweiten Vertriebs f\u00fcr ophthalmologische Ger\u00e4te t\u00e4tig war. In dieser Funktion leitete er die globale Vertriebsstrategie und Marktausf\u00fchrung f\u00fcr ein breites Portfolio diagnostischer und chirurgischer Technologien und spielte eine zentrale Rolle bei der weltweiten Expansion von ZEISS und dem nachhaltigen kommerziellen Wachstum.<\/p>\n
Neben seinen F\u00fchrungsaufgaben ist Andrew ein leidenschaftlicher Bef\u00fcrworter von Innovationen in der Ophthalmologie. Derzeit ist er Mitglied mehrerer Industrie- und Beratungsgremien, darunter ASCRS Foundation, Ophthalmology Foundation, Medical Device Manufacturers Association (MDMA), CEDARS\/ASPENS Industry Committee, AECOS Executive Committee, Ophthalmic World Leaders (OWL), EyeSustain und Gr\u00fcndungsmitglied der Vanguard Ophthalmology Society. Zuvor war er im Vorstand von MicroOptx sowie Pr\u00e4sident und Vorstandsmitglied von FCI Ophthalmics Inc \/ FCI SAS und der American Glaucoma Society Foundation.<\/p>\n
Andrew Chang hat einen Bachelor of Science in Management von der Rutgers University \u2013 Newark.[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=“stretch_row“ css=“.vc_custom_1639056771797{padding-top: 0px !important;padding-bottom: 40px !important;background-color: #ffffff !important;}“][vc_column width=“1\/4″][vc_single_image image=“6222″ img_size=“full“ el_class=“no-mb“][\/vc_column][vc_column width=“3\/4″][vc_column_text el_class=“directors no-mb“]<\/p>\n
Andrew (Andy) Dawson verf\u00fcgt \u00fcber mehr als 20 Jahre Erfahrung im Bereich Personalstrategie und -management, die er bei einigen der weltweit f\u00fchrenden Gesundheits- und Biopharmaunternehmen erworben hat. Andy Dawson begann seine Karriere in der Personalabteilung von Eli Lilly and Company und baute seine Karriere durch progressive HR-F\u00fchrungspositionen sowohl bei Novartis als auch bei Roche rund um den Globus weiter aus, einschlie\u00dflich der Gr\u00fcndung des Impfstoff- und Diagnostikgesch\u00e4fts nach der \u00dcbernahme von Chiron durch Novartis. Als er 2014 zu Shire kam, spielte er eine wichtige F\u00fchrungsrolle bei der Neugestaltung der globalen HR-Funktion in einer bedeutenden Zeit der Transformation. In dieser Zeit f\u00fchrte er das Unternehmen durch bedeutende Ver\u00e4nderungen und Wachstum nach zahlreichen Fusionen und \u00dcbernahmen, einschlie\u00dflich der Leitung der neuen globalen Standortstrategie nach der 32-Milliarden-Dollar-\u00dcbernahme von Baxalta und der Entwicklung und Umsetzung des neuen Organisationsdesigns f\u00fcr das erweiterte Unternehmen. Im Anschluss daran war Andrew Dawson in immer umfangreicheren und verantwortungsvolleren Positionen bei TripAdvisor t\u00e4tig und leitete zuletzt die Personalabteilung f\u00fcr aufstrebende, vorkommerzielle Unternehmen im Bereich Biotechnologie. Andrew Dawson ist Mitglied des Forbes HR Leadership Council und sitzt in den Beir\u00e4ten von LEAP HR und BioPharma Talent \/ CBI. Andrew Dawson hat einen Master-Abschluss in Personalmanagement und -entwicklung von der University of Salford (Manchester, UK).[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=“stretch_row“ css=“.vc_custom_1639056771797{padding-top: 0px !important;padding-bottom: 40px !important;background-color: #ffffff !important;}“][vc_column width=“1\/4″][vc_single_image image=“6220″ img_size=“full“ el_class=“no-mb“][\/vc_column][vc_column width=“3\/4″][vc_column_text el_class=“directors no-mb“]<\/p>\n
Mikhail Boukhny verf\u00fcgt \u00fcber 25 Jahre F\u00fchrungserfahrung in der chirurgischen Ophthalmologie. Bis 2018 leitete er die Forschung und Entwicklung der chirurgischen Instrumente von Alcon in den Bereichen Katarakt, Vitreoretinal, Refraktiv und Diagnostik. Mikhail war bei Alcon erfolgreich t\u00e4tig und hat viele bahnbrechende Produkte entwickelt, darunter den Torsions-Ultraschall und das Centurion Vision System. Er verbindet ein umfassendes Verst\u00e4ndnis f\u00fcr den ungedeckten klinischen und gesch\u00e4ftlichen Bedarf mit der F\u00e4higkeit, bahnbrechende Innovationen zum kommerziellen Erfolg zu f\u00fchren und starke Teams aufzubauen. Mikhail Boukhny ist Inhaber von \u00fcber 70 Patenten; w\u00e4hrend seiner Zeit bei Alcon wurde er wiederholt f\u00fcr seine Leistungen ausgezeichnet, unter anderem mit dem renommierten Novartis VIVA Award. Zuletzt leitete Mikhail Boukhny die chirurgische Forschungs- und Entwicklungsabteilung von Zeiss MediTec, Ophthalmologie, wo er neben Ger\u00e4ten auch f\u00fcr IOL, IOL-Zuf\u00fchrungssysteme und OVD verantwortlich war. Dr. Boukhny erwarb seinen M.S. in Biophysik am Moskauer Institut f\u00fcr Physik und Technologie und seinen Doktortitel in Physik an der Universit\u00e4t von Virginia.[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=“stretch_row“ css=“.vc_custom_1639056771797{padding-top: 0px !important;padding-bottom: 40px !important;background-color: #ffffff !important;}“][vc_column width=“1\/4″][vc_single_image image=“6225″ img_size=“full“ el_class=“no-mb“][\/vc_column][vc_column width=“3\/4″][vc_column_text el_class=“directors no-mb“]<\/p>\n
Jean-Nicolas (\u201eJN\u201c) Fassin verf\u00fcgt \u00fcber 20 Jahre Erfahrung in den Bereichen M&A, Unternehmensfinanzierung, Strategie und Recht. Er kam nach der \u00dcbernahme von PhysIOL\u00ae durch BVI Ende 2018 zum F\u00fchrungsteam von BVI. Bevor er 2017 zu PhysIOL\u00ae kam, war JN Senior Manager bei BDO Corporate Finance in Belgien und beriet Kunden bei kleinen und mittelgro\u00dfen M&A-Transaktionen, Bewertungen und Financial Due Diligence in verschiedenen Branchen. Er arbeitete auch als Unternehmensberater bei McKinsey & Company mit Schwerpunkt auf Strategieaufgaben und als Anwalt in erstklassigen Anwaltskanzleien, wo er Kunden bei Fusionen und \u00dcbernahmen, Rechtsstreitigkeiten und gesellschaftsrechtlichen Angelegenheiten beriet. Er hat einen MBA von der London Business School, einen LLM von der Columbia Law School und ist Absolvent der Sciences Po Paris und der Universit\u00e4t L\u00fcttich, Fakult\u00e4t f\u00fcr Rechtswissenschaften.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"
[vc_row full_width=“stretch_row_content_no_spaces“ el_class=“procedure-hero“][vc_column][vc_single_image image=“2840″ img_size=“full“ alignment=“center“ el_class=“no-mb infinite-image desktop-image“][vc_single_image image=“3347″ img_size=“full“ alignment=“center“ el_class=“no-mb infinite-image mobile-image“][vc_custom_heading text=“Management Team“ font_container=“tag:h1|text_align:left|color:%23ffffff|line_height:1″ use_theme_fonts=“yes“][vc_raw_html el_class=“no-mb“]JTNDaDYlMjBjbGFzcyUzRCUyMmhlYWQtYnJlYWRjcnVtYiUyMiUzRSUzQ2ElMjBocmVmJTNEJTIyJTJGZGUlMkYlMjIlM0VTdGFydHNlaXRlJTNDJTJGYSUzRSUyMCUyRiUyME1hbmFnZW1lbnR0ZWFtJTNDJTJGaDYlM0U=[\/vc_raw_html][\/vc_column][\/vc_row][vc_row full_width=“stretch_row“ css=“.vc_custom_1639056771797{padding-top: 0px !important;padding-bottom: 40px !important;background-color: #ffffff !important;}“][vc_column width=“1\/4″][vc_single_image image=“6205″ img_size=“full“ el_class=“no-mb“][\/vc_column][vc_column width=“3\/4″][vc_column_text el_class=“directors no-mb“] Jim Hollingshead President & Chief Executive Officer Jim Hollingshead verf\u00fcgt \u00fcber mehr als drei Jahrzehnte globale F\u00fchrungserfahrung in der Medizintechnik […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"fullwidth.php","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"class_list":["post-1757","page","type-page","status-publish","hentry"],"acf":[],"rankMath":{"parentDomain":"www.bvimedical.com","noFollowDomains":[],"noFollowExcludeDomains":[],"noFollowExternalLinks":false,"featuredImageNotice":"Das angezeigte Beitragsbild sollte mindestens 200x200 px gro\u00df sein, damit Facebook und andere Social-Media-Websites es \u00fcbernehmen.","pluginReviewed":false,"postSettings":{"linkSuggestions":true,"useFocusKeyword":false},"frontEndScore":false,"postName":"managementteam","permalinkFormat":"https:\/\/www.bvimedical.com\/de\/%pagename%\/","showLockModifiedDate":true,"assessor":{"focusKeywordLink":"https:\/\/www.bvimedical.com\/de\/wp-admin\/edit.php?focus_keyword=%focus_keyword%&post_type=%post_type%","hasTOCPlugin":false,"primaryTaxonomy":false,"serpData":{"title":"BVI Medical\u00a0\u2013\u00a0Managementteam","description":"Das Managementteam von BVI besteht aus F\u00fchrungspersonen mit Erfahrung im Gesundheitswesen und in den Bereichen Kommerzialisierung, Marketing und Finanzen.","focusKeywords":"Managementteam","pillarContent":false,"canonicalUrl":"","breadcrumbTitle":"","advancedRobots":[],"facebookTitle":"","facebookDescription":"","facebookImage":"","facebookImageID":"","facebookHasOverlay":false,"facebookImageOverlay":"","facebookAuthor":"","twitterCardType":"","twitterUseFacebook":true,"twitterTitle":"","twitterDescription":"","twitterImage":"","twitterImageID":"","twitterHasOverlay":false,"twitterImageOverlay":"","twitterPlayerUrl":"","twitterPlayerSize":"","twitterPlayerStream":"","twitterPlayerStreamCtype":"","twitterAppDescription":"","twitterAppIphoneName":"","twitterAppIphoneID":"","twitterAppIphoneUrl":"","twitterAppIpadName":"","twitterAppIpadID":"","twitterAppIpadUrl":"","twitterAppGoogleplayName":"","twitterAppGoogleplayID":"","twitterAppGoogleplayUrl":"","twitterAppCountry":"","robots":{"index":true},"twitterAuthor":"Benutzername","primaryTerm":0,"authorName":"gds","titleTemplate":"%title% %sep% %sitename%","descriptionTemplate":"%excerpt%","showScoreFrontend":true,"lockModifiedDate":false},"powerWords":["abgelenkt","abgesturzt","absolut","abstossend","aburd","abweisen","adaquat","aggressiv","ahnungslos","akkurat","alarmierend","alarmiert","albtraum","all-inclusive","allererste","allererster","allererstes","alleswisser","am schlechtesten","am wichtigsten","angewidert","angriff","angsteinflossend","angstlich","animiert","ankundigung","anonym","anpassbar","anspruchslos","anstossig","antagonistisch","apokalypse","applaus","argumentativ","arm","armageddon","arrogant","atemberaubend","attacke","attraktiv","aufdeckend","aufgebracht","aufgedeckt","aufgeregt","aufheiternd","aufregend","aufregende","aufregenden","aufregung","aufstachelnd","aufstandisch","aufsteigend","auftreibend","augenoffnend","ausgelassen","ausgeruht","ausgespielt","ausgewahlt","ausgewuhlt","ausnutzen","aussergewohnlich","autark","authentisch","autoritat","backdoor","badass","beangstigend","bedenklich","bedingungslos","bedrohen","bedroht","beforderung","befreit","befriedigend","befriedigt","begehren","begeistern","begeistert","begeisterung","beherzt","behind the scenes","beichte","beleidigung","belohnung","bemerkenswert","beneiden","bequem","beruhmt","beschadigen","beschamend","beschmutzt","beschuldigen","beschutzen","besitz","bessesen","bestatigen","bestatigt","beste","bestimmt","bestrafen","betrug","betrugen","bewahrt","bewiesen","bewiesenermassen","bewusst","bezahlbar","bezaubernd","bizarre","bleich","blendend","blut","blutbad","blutig","bombe","bonanza","bonus","bosartig","bose","boshaft","brilliant","brodelnd","brutal","budget","bullshit","bully","bunt","bunte","bunten","case study","cash","challenge","challgene","chaos","cheat-sheet","clever","content","cool","courage","dankbar","daruber redet keiner","deadline","definitiv","dekadent","demoralisierend","demut","desillusioniert","detailiert","diagnose","die wahrheit","direkt","disastros","discount","dokument","dollar","dominieren","doppelt","download","dreckig","dreifach","dreistigkeit","dringend","dringlichkeit","dumm","dummkopf","dummlich","durchbruch","duselig","dynamik","echt","effektiv","effizient","ehrlich","eier","eifersuchtig","eifrig","eindeutig","eindrucksvoll","eine stufe besser","einfach","einfachheit","einfallsreich","eingebildet","eingeschrankt","eingesperrt","einmalig","einsam","eintauchen","einzigartig","eisern","eliminieren","elite","empathie","empfehle","empfehlen","endeffekt","energie","energisch","enorm","entdecken","entfesselt","entfremdet","enthullen","enthullung","enthusiastisch","entmachtet","entsetzlich","entspannt","entzuckend","entzunden","epidemisch","episch","erbarmlich","erfolg","erfolgreich","erfolgsbilanz","erfreut","erfullen","erfullt","ergebnisse","ergreifen","erhaben","erheben","erhohen","erledigt","ermachtigt","ermudet","ernmutigt","ernsthaft","erobern","erroten","errungenschaft","erschaffen","erschrocken","ersehnen","ersparnisse","erstattbar","erstatten","erstaunlich","erste","ertrinken","essentiell","ethisch","euphorisch","exakt","exklusiv","exklusivitat","exkuisit","experte","explodieren","explosiv","exposed","extrem","exzellent","fahig","fahigkeiten","fail","falle","fantasie","fantastischen","farbenfroh","farbenfrohe","faszinierend","faszinierende","faul","faux pas","faux","fehler","feindselig","feldstudie","fesselnd","festlich","festmahl","festplatte","final","flirt","fluchtling","flussig","fokus","fokussiert","folter","formel","frech","freebie","frei","freiheit","freudig","friedlich","frohlich","frohlichkeit","frustriert","fundamental","fur immer","furchtbar","furchtlos","gangster","garantiert","geblendet","geehrt","gefahr","gefahrlich","gefangen","gefangnis","gefeuert","gegensatzlich","gehassig","geheimnis","geheimnisse","geil","geisseln","geist","geistesgestort","gelassen","geld zuruck","geld","genial","gepackt","gerade angekommen","gerissen","geschenk","geschmuggelt","geschutzt","gestandnis","gestandnisse","gestopft","gestresst","gesucht","gesund","getauscht","getestet","getotet","gewaltig","gewalttatig","gewidmet","gewinnspiel","gier","gierig","gift","giftig","gigantisch","giveaway","glamourose","glanzend","glaube","glaubwurdig","gleichmassig","glittering","glitzernde","gluckselig","golden","grandios","grandiose","grandiosen","grandioses","grauenhaft","grausamkeit","grinsen","groesste","gross","grossartig","grossartig","grossartige","grossartigen","grossartiger","grossartiges","grosse","grossen","grosste","grosszugig","grotesk","grube","grundlegend","gruselig","gunstig","hack","hamisch","hammer","handelsgeheimnis","hartnackig","hass","heilig","heimlich","heisshunger","heisshungrig","heiter","held","hell","herablassend","herausfordernd","herausforderung","herausvorderung","herrlichen","herrschend","hervorragend","herz","herzbrechend","herzerwahrmend","heute","hightech","hilflosigkeit","hilfreich","hilfsbereit","himmlisch","hinterhaltig","hoax","hocheffektiv","hochnasig","hochste","hoffnung","hoffnungsvoll","holle","holocaust","horror","how to","humor","hungrige","hurrikan","hypnotisch","hypnotisierend","idiot","idiotisch","illegal","immer","informativ","inhalt","inkompetent","innovativ","insider","inspirierend","inspiriert","intelligent","intensiv","interessant","interessante","invasion","investment","ist da","jackpot","jederzeit kundigen","jetzt","jubilant","jumpstart","jung","kadaver","kampf","katapult","katastrophe","kaufen","kein risiko","keine verpflichtung","kickstart","kindisch","kitschig","klaglich","klar","knast","kollabieren","kollosal","komfortabel","komisch","kompetitiv","komplett","kompromiss","komsich","konstruktiv","kontrollierend","kontrollverlust","kooperativ","kopie","korrupt","kostenlos","kraftlos","kraftvoll","krankhaft","kreativ","kreative","kriese","kritisch","kruppel","lachen","lacherlich","lahm","last minute","lauernd","lebendig","lebenslanglich","lecken","lecker","legendar","legitim","leiche","leicht","leiden","leider","leise","letzte chance","letzte","leuchtend","liberal","licht","liebe","liebenswurdig","liebevoll","life-changing","limitiert","lohnend","loser","losung","lugen","lugend","lukrativ","lust","lustig","lustige","lustigsten","luxorios","magisch","mainstream","mammut","manipulativ","massiv","masterclass","meditierend","meiseter","meistverkauft","meltdown","millionen","mind-blowing","minderwertig","minimalist","missbrauch","misstrauisch","mittelmassig","mittig","modern","moderne","moglichkeiten","monetarisieren","monumental","mord","motiviert","muhelos","muhevoll","mull","mut","mutig","nachmachen","nachteile","nackt","nagel","naiv","natural","nazi","neid","nervos","neu","niedertrachtig","niemals","notfall","notiert","nutzlich","nutzlos","offensichtlich","offiziel","offnen","ohne hintergedanken","ok","okay","okonomisch","on-demand","opfer","optimistisch","overnight","packend","panik","panzer","paralisiert","pas","passioniert","pause","payback","peinlich","perfekt","perplex","perskeptive","pessimistisch","pfund","piranha","pleite","plotzlich","pochend","polarisierend","popular","portfolio","praktisch","preis","prestige","privat","privatsphare","priviligiert","problem","produktiv","professionell","profit","profitabel","provokativ","provozierend","prozess","psychologisch","qual","qualen","qualitat","rabatt","rache","rachsuchtig","raffiniert","rasend","rat","rau","recherche","reduziert","reflektieren","regeln","reich","reiche","reichtum","relaxed","report","responsive","revolutionar","riesig","risiko","riskant","riskieren","rotzfrech","rowdy","ruckrat","ruckschlag","rucksichtlos","ruhig","ruiniert","sabotiert","sadistisch","sale","sarkastisch","scam","schabig","schadigend","schadlich","schamlos","schatz","schicksal","schlachten","schlafen","schlag","schlau","schlimm","schmerzhaft","schmerzlos","schmuggel","schnell","schnellstart","schokierend","schonheit","schrecklich","schreien","schritt fur schritt","schuld","schuldlos","schwach","schwarm","schwarzmarkt","schwerkraft","schwinden","sechsstellig","sehenswerte","selbsthass","selten","sensationell","sex","sexy","sicher","sicherheit","sicherlich","sieg","sill","simpel","sinnlich","sinnlos","skandal","skandalos","skill","sklave","sneak-peek","snob","sofort gespart","sofort","sollte","sonnig","sonnige","sonnigen","sorgen","sorgfaltig","sorglos","spannend","sparen","sparsam","spass","spassig","spektakular","speziell","spielen","spoiler","spontan","spotlight","stabil","stark","start","stoisch","stolz","stop","strahlend","strangulieren","strategie","studien","stumperhaft","stur","sunden","sundigend","super","superb","survival","tapfer","tauschend","teaser","technologie","terror","terrorist","teuer","tief","tiefgreifend","tierisch","tod","todlich","toll","tolle","toller","tortur","tot","tote","toten","totend","toxisch","tragisch","tragodie","transfomieren","transparenz","trauma","traumatisiert","traurigkeit","trend","tricks","trigger","triumpf","trocken","trotz","trugerisch","tweaks","tyrann","ubel","uberfordert","uberkommen","uberleben","uberlegen","uberraschend","uberrascht","uberraschung","uberwaltigend","uberwinden","ultimativ","umfassend","umstritten","umwerfend","unatorisiert","unaufhaltbar","unausgelasted","unbedacht","unbeliebt","unbeschwert","unbewusst","undercover","undokumentiert","unehrlich","unentschlossen","unerwartet","unfahig","ungeduldig","ungedult","ungehort","ungemutlich","ungerechtfertigt","ungesehen","ungetrubt","ungewohnlich","ungezogen","unglaublich","unglaubliches","uninteressiert","unkontrollierbar","unkonventionell","unlimitiert","unpenetrierbar","unschuldig","unsicher","unstabil","unter verschluss","untergrund","unterhaltsam","unterstutz","unterstutzend","unubertroffen","unvergesslich","unverneinbar","unvoreingenommen","unwiderstehlich","unwirtlich","unzensiert","unzuverlassig","up-selling","vaporisieren","verangstigt","verantwortlich","verargert","verarscht","verbessert","verbluffend","verblufft","verboten","verbreiten","verdachtig","verdammt","verdeckt","vereinfacht","verfuhrend","vergebend","vergessen","vergleich","verhauen","verifizieren","verkommen","verlegen","verletzbar","verletzt","verlockend","verloren","vermasselt","vermeiden","vermogen","vernichten","vernichtend","vernunftig","veroffentlichung","verpassen","verraterisch","verruckt","versagen","verschwitzt","versichert","verspielt","versprechend","versteckt","vertrauenswurdig","vertraulich","vertraumt","verurteilend","verwunderlich","verwundet","verzaubernd","verzweifelt","vierfach","vogelfrei","vollig","vollstandig","vorsicht","vorstellungskraft","vorteil","wachstum","wagemutig","wahnsinn","wahnsinnig","wahrhaftig","wahrheit","wahrheitsgemass","wahrscheinlich","warnung","was dir keiner sagt","wehleidig","welt","wenig bekannt","wert","wertvoll","wichtig","widerlich","wiedererkannt","wild","wilde","wilden","willensstarke","wirr","wohltatigkeit","wortlich","wunder","wunderbar","wunderbaren","wunderschon","wutend","zeichen","zeitig","zen","zensiert","zerschlagen","zerschmetternd","zerstorend","zertifiziert","zielorientiert","zischend","zischt","zocken","zogernd","zugeben","zuruckgehalten","zuruckgelassen","zuruckweisen","zusatzlich","zutaten","zuverlassig","zwangsernahrt","zweifelnd","zwickend","zwingend","einfache","einfachen","einfaches","einfacher","simple","simplen","simples","simpler","besten","bestes","bester","beste","bestbewertet","bestbewerteten","bestbewertete","bestbewerteter","bestbewertetes","\u00fcberraschende","\u00fcberraschenden","\u00fcberraschendes","\u00fcberraschender","hilfreiche","hilfreiches","hilfreichen","hilfreicher","f\u00f6rdern","unterst\u00fctzen","helfen","spielerisch","spannende","spannendes","spannenden","spannender","gro\u00dfartige","gro\u00dfartiges","gro\u00dfartigen","gro\u00dfartiger","ideal","ideales","idealen","idealer","faszinierend","faszinierendes","faszinierenden","faszinierender","wichtig","wichtige","wichtiges","wichtigen","wichtiger","sicher","sichere","sicheres","sicheren","sicherer","umfassende","umfassendes","umfassenden","umfassender","ultimative","ultimatives","ultimativen","ultimativer","einzigartige","einzigartiges","einzigartigen","einzigartiger"],"diacritics":{"A":"[\\u0041\\u24B6\\uFF21\\u00C0\\u00C1\\u00C2\\u1EA6\\u1EA4\\u1EAA\\u1EA8\\u00C3\\u0100\\u0102\\u1EB0\\u1EAE\\u1EB4\\u1EB2\\u0226\\u01E0\\u01DE\\u1EA2\\u00C5\\u01FA\\u01CD\\u0200\\u0202\\u1EA0\\u1EAC\\u1EB6\\u1E00\\u0104\\u023A\\u2C6F]","AA":"[\\uA732]","AE":"[\\u00C6\\u01FC\\u01E2\\u00C4]","AO":"[\\uA734]","AU":"[\\uA736]","AV":"[\\uA738\\uA73A]","AY":"[\\uA73C]","B":"[\\u0042\\u24B7\\uFF22\\u1E02\\u1E04\\u1E06\\u0243\\u0182\\u0181]","C":"[\\u0043\\u24B8\\uFF23\\u0106\\u0108\\u010A\\u010C\\u00C7\\u1E08\\u0187\\u023B\\uA73E]","D":"[\\u0044\\u24B9\\uFF24\\u1E0A\\u010E\\u1E0C\\u1E10\\u1E12\\u1E0E\\u0110\\u018B\\u018A\\u0189\\uA779]","DZ":"[\\u01F1\\u01C4]","Dz":"[\\u01F2\\u01C5]","E":"[\\u0045\\u24BA\\uFF25\\u00C8\\u00C9\\u00CA\\u1EC0\\u1EBE\\u1EC4\\u1EC2\\u1EBC\\u0112\\u1E14\\u1E16\\u0114\\u0116\\u00CB\\u1EBA\\u011A\\u0204\\u0206\\u1EB8\\u1EC6\\u0228\\u1E1C\\u0118\\u1E18\\u1E1A\\u0190\\u018E]","F":"[\\u0046\\u24BB\\uFF26\\u1E1E\\u0191\\uA77B]","G":"[\\u0047\\u24BC\\uFF27\\u01F4\\u011C\\u1E20\\u011E\\u0120\\u01E6\\u0122\\u01E4\\u0193\\uA7A0\\uA77D\\uA77E]","H":"[\\u0048\\u24BD\\uFF28\\u0124\\u1E22\\u1E26\\u021E\\u1E24\\u1E28\\u1E2A\\u0126\\u2C67\\u2C75\\uA78D]","I":"[\\u0049\\u24BE\\uFF29\\u00CC\\u00CD\\u00CE\\u0128\\u012A\\u012C\\u0130\\u00CF\\u1E2E\\u1EC8\\u01CF\\u0208\\u020A\\u1ECA\\u012E\\u1E2C\\u0197]","J":"[\\u004A\\u24BF\\uFF2A\\u0134\\u0248]","K":"[\\u004B\\u24C0\\uFF2B\\u1E30\\u01E8\\u1E32\\u0136\\u1E34\\u0198\\u2C69\\uA740\\uA742\\uA744\\uA7A2]","L":"[\\u004C\\u24C1\\uFF2C\\u013F\\u0139\\u013D\\u1E36\\u1E38\\u013B\\u1E3C\\u1E3A\\u0141\\u023D\\u2C62\\u2C60\\uA748\\uA746\\uA780]","LJ":"[\\u01C7]","Lj":"[\\u01C8]","M":"[\\u004D\\u24C2\\uFF2D\\u1E3E\\u1E40\\u1E42\\u2C6E\\u019C]","N":"[\\u004E\\u24C3\\uFF2E\\u01F8\\u0143\\u00D1\\u1E44\\u0147\\u1E46\\u0145\\u1E4A\\u1E48\\u0220\\u019D\\uA790\\uA7A4]","NJ":"[\\u01CA]","Nj":"[\\u01CB]","O":"[\\u004F\\u24C4\\uFF2F\\u00D2\\u00D3\\u00D4\\u1ED2\\u1ED0\\u1ED6\\u1ED4\\u00D5\\u1E4C\\u022C\\u1E4E\\u014C\\u1E50\\u1E52\\u014E\\u022E\\u0230\\u022A\\u1ECE\\u0150\\u01D1\\u020C\\u020E\\u01A0\\u1EDC\\u1EDA\\u1EE0\\u1EDE\\u1EE2\\u1ECC\\u1ED8\\u01EA\\u01EC\\u00D8\\u01FE\\u0186\\u019F\\uA74A\\uA74C]","OE":"[\\u00D6]","OI":"[\\u01A2]","OO":"[\\uA74E]","OU":"[\\u0222]","P":"[\\u0050\\u24C5\\uFF30\\u1E54\\u1E56\\u01A4\\u2C63\\uA750\\uA752\\uA754]","Q":"[\\u0051\\u24C6\\uFF31\\uA756\\uA758\\u024A]","R":"[\\u0052\\u24C7\\uFF32\\u0154\\u1E58\\u0158\\u0210\\u0212\\u1E5A\\u1E5C\\u0156\\u1E5E\\u024C\\u2C64\\uA75A\\uA7A6\\uA782]","S":"[\\u0053\\u24C8\\uFF33\\u1E9E\\u015A\\u1E64\\u015C\\u1E60\\u0160\\u1E66\\u1E62\\u1E68\\u0218\\u015E\\u2C7E\\uA7A8\\uA784]","T":"[\\u0054\\u24C9\\uFF34\\u1E6A\\u0164\\u1E6C\\u021A\\u0162\\u1E70\\u1E6E\\u0166\\u01AC\\u01AE\\u023E\\uA786]","TZ":"[\\uA728]","U":"[\\u0055\\u24CA\\uFF35\\u00D9\\u00DA\\u00DB\\u0168\\u1E78\\u016A\\u1E7A\\u016C\\u01DB\\u01D7\\u01D5\\u01D9\\u1EE6\\u016E\\u0170\\u01D3\\u0214\\u0216\\u01AF\\u1EEA\\u1EE8\\u1EEE\\u1EEC\\u1EF0\\u1EE4\\u1E72\\u0172\\u1E76\\u1E74\\u0244]","UE":"[\\u00DC]","V":"[\\u0056\\u24CB\\uFF36\\u1E7C\\u1E7E\\u01B2\\uA75E\\u0245]","VY":"[\\uA760]","W":"[\\u0057\\u24CC\\uFF37\\u1E80\\u1E82\\u0174\\u1E86\\u1E84\\u1E88\\u2C72]","X":"[\\u0058\\u24CD\\uFF38\\u1E8A\\u1E8C]","Y":"[\\u0059\\u24CE\\uFF39\\u1EF2\\u00DD\\u0176\\u1EF8\\u0232\\u1E8E\\u0178\\u1EF6\\u1EF4\\u01B3\\u024E\\u1EFE]","Z":"[\\u005A\\u24CF\\uFF3A\\u0179\\u1E90\\u017B\\u017D\\u1E92\\u1E94\\u01B5\\u0224\\u2C7F\\u2C6B\\uA762]","a":"[\\u0061\\u24D0\\uFF41\\u1E9A\\u00E0\\u00E1\\u00E2\\u1EA7\\u1EA5\\u1EAB\\u1EA9\\u00E3\\u0101\\u0103\\u1EB1\\u1EAF\\u1EB5\\u1EB3\\u0227\\u01E1\\u01DF\\u1EA3\\u00E5\\u01FB\\u01CE\\u0201\\u0203\\u1EA1\\u1EAD\\u1EB7\\u1E01\\u0105\\u2C65\\u0250]","aa":"[\\uA733]","ae":"[\\u00E6\\u01FD\\u01E3\\u00E4]","ao":"[\\uA735]","au":"[\\uA737]","av":"[\\uA739\\uA73B]","ay":"[\\uA73D]","b":"[\\u0062\\u24D1\\uFF42\\u1E03\\u1E05\\u1E07\\u0180\\u0183\\u0253]","c":"[\\u0063\\u24D2\\uFF43\\u0107\\u0109\\u010B\\u010D\\u00E7\\u1E09\\u0188\\u023C\\uA73F\\u2184]","d":"[\\u0064\\u24D3\\uFF44\\u1E0B\\u010F\\u1E0D\\u1E11\\u1E13\\u1E0F\\u0111\\u018C\\u0256\\u0257\\uA77A]","dz":"[\\u01F3\\u01C6]","e":"[\\u0065\\u24D4\\uFF45\\u00E8\\u00E9\\u00EA\\u1EC1\\u1EBF\\u1EC5\\u1EC3\\u1EBD\\u0113\\u1E15\\u1E17\\u0115\\u0117\\u00EB\\u1EBB\\u011B\\u0205\\u0207\\u1EB9\\u1EC7\\u0229\\u1E1D\\u0119\\u1E19\\u1E1B\\u0247\\u025B\\u01DD]","f":"[\\u0066\\u24D5\\uFF46\\u1E1F\\u0192\\uA77C]","g":"[\\u0067\\u24D6\\uFF47\\u01F5\\u011D\\u1E21\\u011F\\u0121\\u01E7\\u0123\\u01E5\\u0260\\uA7A1\\u1D79\\uA77F]","h":"[\\u0068\\u24D7\\uFF48\\u0125\\u1E23\\u1E27\\u021F\\u1E25\\u1E29\\u1E2B\\u1E96\\u0127\\u2C68\\u2C76\\u0265]","hv":"[\\u0195]","i":"[\\u0069\\u24D8\\uFF49\\u00EC\\u00ED\\u00EE\\u0129\\u012B\\u012D\\u00EF\\u1E2F\\u1EC9\\u01D0\\u0209\\u020B\\u1ECB\\u012F\\u1E2D\\u0268\\u0131]","j":"[\\u006A\\u24D9\\uFF4A\\u0135\\u01F0\\u0249]","k":"[\\u006B\\u24DA\\uFF4B\\u1E31\\u01E9\\u1E33\\u0137\\u1E35\\u0199\\u2C6A\\uA741\\uA743\\uA745\\uA7A3]","l":"[\\u006C\\u24DB\\uFF4C\\u0140\\u013A\\u013E\\u1E37\\u1E39\\u013C\\u1E3D\\u1E3B\\u017F\\u0142\\u019A\\u026B\\u2C61\\uA749\\uA781\\uA747]","lj":"[\\u01C9]","m":"[\\u006D\\u24DC\\uFF4D\\u1E3F\\u1E41\\u1E43\\u0271\\u026F]","n":"[\\u006E\\u24DD\\uFF4E\\u01F9\\u0144\\u00F1\\u1E45\\u0148\\u1E47\\u0146\\u1E4B\\u1E49\\u019E\\u0272\\u0149\\uA791\\uA7A5]","nj":"[\\u01CC]","o":"[\\u006F\\u24DE\\uFF4F\\u00F2\\u00F3\\u00F4\\u1ED3\\u1ED1\\u1ED7\\u1ED5\\u00F5\\u1E4D\\u022D\\u1E4F\\u014D\\u1E51\\u1E53\\u014F\\u022F\\u0231\\u022B\\u1ECF\\u0151\\u01D2\\u020D\\u020F\\u01A1\\u1EDD\\u1EDB\\u1EE1\\u1EDF\\u1EE3\\u1ECD\\u1ED9\\u01EB\\u01ED\\u00F8\\u01FF\\u0254\\uA74B\\uA74D\\u0275]","oe":"[\\u00f6]","oi":"[\\u01A3]","ou":"[\\u0223]","oo":"[\\uA74F]","p":"[\\u0070\\u24DF\\uFF50\\u1E55\\u1E57\\u01A5\\u1D7D\\uA751\\uA753\\uA755]","q":"[\\u0071\\u24E0\\uFF51\\u024B\\uA757\\uA759]","r":"[\\u0072\\u24E1\\uFF52\\u0155\\u1E59\\u0159\\u0211\\u0213\\u1E5B\\u1E5D\\u0157\\u1E5F\\u024D\\u027D\\uA75B\\uA7A7\\uA783]","s":"[\\u0073\\u24E2\\uFF53\\u015B\\u1E65\\u015D\\u1E61\\u0161\\u1E67\\u1E63\\u1E69\\u0219\\u015F\\u023F\\uA7A9\\uA785\\u1E9B]","ss":"[\\u00DF]","t":"[\\u0074\\u24E3\\uFF54\\u1E6B\\u1E97\\u0165\\u1E6D\\u021B\\u0163\\u1E71\\u1E6F\\u0167\\u01AD\\u0288\\u2C66\\uA787]","tz":"[\\uA729]","u":"[\\u0075\\u24E4\\uFF55\\u00F9\\u00FA\\u00FB\\u0169\\u1E79\\u016B\\u1E7B\\u016D\\u01DC\\u01D8\\u01D6\\u01DA\\u1EE7\\u016F\\u0171\\u01D4\\u0215\\u0217\\u01B0\\u1EEB\\u1EE9\\u1EEF\\u1EED\\u1EF1\\u1EE5\\u1E73\\u0173\\u1E77\\u1E75\\u0289]","ue":"[\\u00FC]","v":"[\\u0076\\u24E5\\uFF56\\u1E7D\\u1E7F\\u028B\\uA75F\\u028C]","vy":"[\\uA761]","w":"[\\u0077\\u24E6\\uFF57\\u1E81\\u1E83\\u0175\\u1E87\\u1E85\\u1E98\\u1E89\\u2C73]","x":"[\\u0078\\u24E7\\uFF58\\u1E8B\\u1E8D]","y":"[\\u0079\\u24E8\\uFF59\\u1EF3\\u00FD\\u0177\\u1EF9\\u0233\\u1E8F\\u00FF\\u1EF7\\u1E99\\u1EF5\\u01B4\\u024F\\u1EFF]","z":"[\\u007A\\u24E9\\uFF5A\\u017A\\u1E91\\u017C\\u017E\\u1E93\\u1E95\\u01B6\\u0225\\u0240\\u2C6C\\uA763]"},"researchesTests":["contentHasTOC","contentHasShortParagraphs","contentHasAssets","keywordInTitle","keywordInMetaDescription","keywordInPermalink","keywordIn10Percent","keywordInContent","keywordInSubheadings","keywordInImageAlt","keywordDensity","keywordNotUsed","lengthContent","lengthPermalink","linksHasInternal","linksHasExternals","linksNotAllExternals","titleStartWithKeyword","titleSentiment","titleHasPowerWords","titleHasNumber","hasContentAI"],"hasRedirection":false,"hasBreadcrumb":false},"homeUrl":"https:\/\/www.bvimedical.com\/de","objectID":1757,"objectType":"post","locale":"de","localeFull":"de_DE","overlayImages":{"play":{"name":"Wiedergabezeichen","url":"https:\/\/www.bvimedical.com\/de\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-play.png","path":"\/nas\/content\/live\/bvi\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-play.png","position":"middle_center"},"gif":{"name":"GIF-Symbol","url":"https:\/\/www.bvimedical.com\/de\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-gif.png","path":"\/nas\/content\/live\/bvi\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-gif.png","position":"middle_center"}},"defautOgImage":"https:\/\/www.bvimedical.com\/de\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/social-placeholder.jpg","customPermalinks":true,"isUserRegistered":false,"autoSuggestKeywords":false,"connectSiteUrl":"https:\/\/rankmath.com\/auth?site=https%3A%2F%2Fwww.bvimedical.com%2Fde&r=https%3A%2F%2Fwww.bvimedical.com%2Fde%2Fwp-json%2Fwp%2Fv2%2Fpages%2F1757%3Fnonce%3D0d2f44f924","maxTags":5,"trendsIcon":"